ASH 2021 | DLBCL updates at ASH 2021
Chan Yoon Cheah
• 22 Nov 2021
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, provides key updates in the field of diffuse large B-cell lymphoma (DLBCL) that will be discussed at ASH 2021. He comments on the results from the Phase III ZUMA-7 trial (NCT03391466) which investigated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) DLBCL. Dr Cheah additionally highlights potential data from the Phase III POLARIX trial (NCT03274492), which compared polatuzumab vedotin, an antibody-drug conjugate, with R-CHP against R-CHOP. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
